56 related articles for article (PubMed ID: 19806910)
1. [Structure-activity relationships analysis of thienorphine and its derivatives].
Yu G; Liu YS; Yan LD; Wen Q; Gong ZH
Yao Xue Xue Bao; 2009 Jul; 44(7):726-30. PubMed ID: 19806910
[TBL] [Abstract][Full Text] [Related]
2. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
Yu G; Yue YJ; Cui MX; Gong ZH
J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of monoamine oxidase activity in the striatum of rats following chronic treatment of thienorphine.
Yong Z; Yan L; Wang X; Su R; Gong Z
Eur J Pharmacol; 2013 Aug; 713(1-3):44-6. PubMed ID: 23665497
[TBL] [Abstract][Full Text] [Related]
4. Effect of thienorphine on the isolated uterine strips from pregnant rats.
Zhou P; Yan L; Yong Z; Yu G; Dong H; Yan H; Su R; Gong Z
Eur J Pharmacol; 2013 Mar; 703(1-3):83-90. PubMed ID: 23416213
[TBL] [Abstract][Full Text] [Related]
5. Multiple mechanisms underlying the long duration of action of thienorphine, a novel partial opioid agonist for the treatment of addiction.
Yu G; Li SH; Cui MX; Yan LD; Yong Z; Zhou PL; Su RB; Gong ZH
CNS Neurosci Ther; 2014 Mar; 20(3):282-8. PubMed ID: 24330593
[TBL] [Abstract][Full Text] [Related]
6. The effect of chronic thienorphine administration on long-term potentiation and synaptic structure in rat hippocampus.
Yong Z; Yan L; Dong Z; Wang X; Su R; Gong Z
Synapse; 2013 Nov; 67(11):779-85. PubMed ID: 23723052
[TBL] [Abstract][Full Text] [Related]
7. Effects of thienorphine on synaptic structure and synaptophysin expression in the rat nucleus accumbens.
Yong Z; Yan L; Gao X; Gong Z; Su R
Neuroscience; 2014 Aug; 274():53-8. PubMed ID: 24861887
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine: new pharmacological aspects.
Cowan A
Int J Clin Pract Suppl; 2003 Feb; (133):3-8; discussion 23-4. PubMed ID: 12665117
[TBL] [Abstract][Full Text] [Related]
9. Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception.
Fischer BD; Dykstra LA
J Pharmacol Exp Ther; 2006 Sep; 318(3):1300-6. PubMed ID: 16772537
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of thienorphine and its active metabolite thienorphine glucuronide in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.
Kong Q; Qiao J; Wang X; Yuan S; Zhang Z; Gong Z; Ruan J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(1):52-61. PubMed ID: 17933594
[TBL] [Abstract][Full Text] [Related]
11. Effects of thienorphine on the contraction of isolated ureter and bladder of guinea pigs.
Zhou P; Li Y; Yong Z; Yan H; Su R; Gong Z
Eur J Pharmacol; 2016 Oct; 789():144-151. PubMed ID: 27445237
[TBL] [Abstract][Full Text] [Related]
12. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
Shannon HE; Cone EJ; Gorodetzky CW
J Pharmacol Exp Ther; 1984 Jun; 229(3):768-74. PubMed ID: 6547177
[TBL] [Abstract][Full Text] [Related]
13. Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.
Obara I; Makuch W; Spetea M; Schütz J; Schmidhammer H; Przewlocki R; Przewlocka B
Eur J Pharmacol; 2007 Mar; 558(1-3):60-7. PubMed ID: 17204264
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
15. A new buprenorphine analogy, thenorphine, inhibits morphine-induced behavioral sensitization in mice.
Zhao WL; Gong ZH; Liang JH
Acta Pharmacol Sin; 2004 Nov; 25(11):1413-8. PubMed ID: 15525461
[TBL] [Abstract][Full Text] [Related]
16. A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
Park HS; Lee HY; Kim YH; Park JK; Zvartau EE; Lee H
Bioorg Med Chem Lett; 2006 Jul; 16(13):3609-13. PubMed ID: 16650985
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
Ohtani M; Kotaki H; Sawada Y; Iga T
J Pharmacol Exp Ther; 1995 Feb; 272(2):505-10. PubMed ID: 7853163
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
19. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
